PAPER
Cesium Carbonate Promoted N-Alkylations of Aromatic Cyclic Imides
575
HRMS (EI): m/z [M]+ calcd for C18H17NO4: 311.1157; found:
N-[3-(Ethoxycarbonyl)propyl]-2,3-pyrazinedicarboximide (5e)
311.1163.
Mp 115–116 °C (MeOH).
1H NMR (CDCl3): d = 9.00 (s, 2 H, H5, H6), 4.03 (q, J = 7.1 Hz, 2
H, OCH2), 3.71 (t, J = 7.0 Hz, 2 H, NCH2), 2.42 (t, J = 7.0 Hz, 2 H,
CH2CO), 1.89 (p, J = 7.0 Hz, 2 H, CH2CH2CH2), 1.17 (t, J = 7.1 Hz,
3 H, CH3).
13C NMR (CDCl3): d = 168.5, 160.9, 144.4, 143.2, 55.9, 30.0, 26.7,
19.2, 10.2.
MS (EI, 20 eV): m/z (%) = 263 (M+, 80), 189 (100).
HRMS (EI): m/z [M]+ calcd for C12H13N3O4: 263.0906; found:
N-[2-(Ethoxycarbonyl)ethyl]-2,3-pyridinedicarboximide (3d)
Mp 59–61 °C (i-PrOH).
1H NMR (CDCl3): d = 8.98 (dd, J = 4.9, 1.5 Hz, 1 H, H6), 8.17 (dd,
J = 7.7, 1.5 Hz, 1 H, H4), 7.63 (dd, J = 7.7, 4.9 Hz, 1 H, H5), 4.13
(q, J = 7.1 Hz, 2 H, OCH2), 4.07 (t, J = 7.2 Hz, 2 H, NCH2), 2.75 (t,
J = 7.2 Hz, 2 H, CH2CO), 1.23 (t, J = 7.1 Hz, 3 H, CH3).
13C NMR (CDCl3): d = 170.6, 166.0, 165.8, 155.3, 151.6, 131.3,
127.5, 127.3, 60.9, 34.0, 32.8, 14.1.
MS (EI, 70 eV): m/z (%) = 248 (M+, 3), 55 (100).
263.0910.
HRMS (EI): m/z [M]+ calcd for C12H12N2O4: 248.0797; found:
248.0782.
Acknowledgment
This work was financially supported by the Universidad de Buenos
Aires.
N-[3-(Ethoxycarbonyl)propyl]-2,3-pyridinedicarboximide (3e)
Mp 60–61 °C (i-PrOH).
1H NMR (CDCl3): d = 8.96 (dd, J = 4.8, 1.6 Hz, 1 H, H6), 8.15 (dd,
J = 7.5, 1.6 Hz, 1 H, H4), 7.61 (dd, J = 7.5, 4.8 Hz, 1 H, H5), 4.09
(q, J = 7.1 Hz, 2 H, OCH2), 3.81 (t, J = 7.3 Hz, 2 H, NCH2), 2.37 (t,
J = 7.3 Hz, 2 H, CH2CO), 2.03 (p, J = 7.3 Hz, 2 H, CH2CH2CH2),
1.22 (t, J = 7.1 Hz, 3 H, CH3).
13C NMR (CDCl3): d = 172.5, 166.3, 166.0, 155.2, 151.7, 131.1,
127.4, 127.3, 60.6, 37.5, 31.5, 23.7, 14.2.
References
(1) Among others, see: (a) Chapman, J. M. Jr.; Sowell, J. W.;
Abdalla, G.; Hall, I. H. J. Pharm. Sci. 1989, 78, 903; and
references cited therein. (b) Raasch, A.; Scharfernstein, O.;
Tränkle, C.; Holzgrabe, U.; Mohr, K. J. Med. Chem. 2002,
45, 3809. (c) Usifoh, C. O.; Lambert, D. M.; Wouters, J.;
Scriba, G. K. E. Arch. Pharm. Pharm. Med. Chem. 2001,
334, 323. (d) Collin, X.; Robert, J.-M.; Wielgosz, G.;
Le Baut, G.; Bobin-Dubigeon, C.; Grimaud, N.; Petit, J.-Y.
Eur. J. Med. Chem. 2001, 36, 639. (e) Muszalska, I.;
Wojtyniak, E. Acta Pol. Pharm. Drug Res. 2007, 64, 319;
and references cited therein. (f) Abdel-Aziz, A. A.-M. Eur.
J. Med. Chem. 2007, 42, 614. (g) Śladowska, H.; Filipek,
B.; Skatula, D.; Sabiniarz, A.; Kardasz, M.; Potoczec, J.;
Sieclucka-Dziuba, M.; Rajtar, G.; Kleinrok, Z.; Lis, T.
Farmaco 2002, 57, 897.
(2) Among others, see: (a) Advanced Organic Chemistry:
Reactions, Mechanisms and Structures, 4th ed.; Smith, M.
B.; March, J., Eds.; John Wiley & Sons: New York, 2001.
(b) Salvi, V. K.; Bhambi, D.; Jat, J. L.; Talesara, G. L.
ARKIVOC 2006, (xiv), 133. (c) Hamprecht, G.; Goetz, N.;
Wuerzer, B.; Westphalen, K.-O. EP 0,422,456, 1991; Chem.
Abstr. 1991, 115, 92084z. (d) Blanco, M. M.; Shmidt, M. S.;
Perillo, I. A. ARKIVOC 2005, (xii), 195; and references cited
therein.
MS (EI, 20 eV): m/z (%) = 262 (M+, 27), 175 (100).
HRMS (EI): m/z [M]+ calcd for C13H14N2O4: 262.0953; found:
262.0958.
N-Butyl-3,4-pyridinedicarboximide (4b)
Oil.
1H NMR (CDCl3): d = 9.14 (s, 1 H, H2), 9.05 (d, J = 4.9 Hz, 1 H,
H6), 7.74 (d, J = 4.9 Hz, 1 H, H5), 3.70 (t, J = 7.4 Hz, 2 H, NCH2),
1.66 (p, J = 7.4 Hz, 2 H, NCH2CH2), 1.37 (s, J = 7.4 Hz, 2 H,
CH2CH3), 0.94 (t, J = 7.4 Hz, 3 H, CH3).
13C NMR (CDCl3): d = 167.2, 166.8, 155.5, 144.6, 139.5, 125.9,
116.7, 38.1, 30.4, 20.0, 13.5.
MS (EI, 70 eV): m/z (%) = 204 (M+, 44), 50 (100).
HRMS (EI): m/z [M]+ calcd for C11H12N2O2: 204.0898; found:
204.0910.
N-Butyl-2,3-pyrazinedicarboximide (5b)
Mp 129–131 °C (MeOH).
(3) Among others, see: (a) Abdel-Monem, M. M.; Newton, N.
E.; Weeks, C. E. J. Med. Chem. 1974, 17, 447.
1H NMR (CDCl3): d = 8.94 (s, 2 H, H5, H6), 3.85 (t, J = 7.3 Hz, 2
H, NCH2), 1.74 (p, J = 7.3 Hz, 2 H, NCH2CH2), 1.42 (s, J = 7.3 Hz,
2 H, CH2CH3), 0.98 (t, J = 7.3 Hz, 3 H, CH3).
13C NMR (CDCl3): d = 164.1, 148.9, 146.9, 38.5, 30.5, 20.1, 13.6.
MS (EI, 20 eV): m/z (%) = 205 (M+, 100).
(b) Gnichtel, H. Chem. Ber. 1965, 98, 567. (c) Furukawa,
Y.; Miki, Y. US 7,135,576, 2006. (d) Schapira, C. B.;
Abasolo, M. I.; Perillo, I. A. J. Heterocycl. Chem. 1985, 22,
577. (e) Hayashi, Y.; Kayatani, T.; Sugimoto, H.; Suzuki,
M.; Inomata, K.; Uehara, A.; Mizutani, Y.; Kitagawa, T.;
Maeda, Y. J. Am. Chem. Soc. 1995, 117, 11220.
HRMS (EI): m/z [M]+ calcd for C10H11N3O2: 205.0851; found:
205.0869.
(4) (a) Śladowska, H.; Filipek, B.; Szkatula, D.; Sapa, J.;
Bednarski, M.; Ciolkowska, M. Farmaco 2005, 60, 53; and
references cited therein. (b) Hara, H. JP 8285386, 1982;
Chem. Abstr. 1982, 97, 198187.
(5) (a) Perillo, I. A.; Kremenchuzky, L.; Blanco, M. M. J. Mol.
Struct. 2009, 921, 307. (b) Blanco, M. M.; Levin, G. J.;
Schapira, C. B.; Perillo, I. A. Heterocycles 2002, 57, 1881.
(6) Among others, see: (a) Blanco, M. M.; Lorenzo, M. G.;
Perillo, I. A.; Schapira, C. B. J. Heterocycl. Chem. 1996, 33,
361. (b) Johnston, T. P.; Piper, J. R.; Stringfellow, C. R.;
Elliot, R. D. J. Med. Chem. 1971, 14, 345. (c) Jacobs, R. L.
US 3525747, 1970; Chem. Abstr. 1970, 73, 98985.
(d) Jaśkowska, J.; Kowalski, P. J. Heterocycl. Chem. 2008,
45, 1371.
N-[2-(Ethoxycarbonyl)ethyl]-2,3-pyrazinedicarboximide (5d)
Mp 111–113 °C (MeOH).
1H NMR (CDCl3): d = 9.02 (s, 2 H, H5, H6), 4.07 (q, J = 7.1 Hz, 2
H, OCH2), 3.91 (t, J = 7.5 Hz, 2 H, NCH2), 2.71 (t, J = 7.5 Hz, 2 H,
CH2CO), 1.17 (t, J = 7.1 Hz, 3 H, CH3).
13C NMR (CDCl3): d = 166.5, 160.4, 144.8, 144.7, 56.3, 30.0, 28.2,
10.1.
MS (EI, 20 eV): m/z (%) = 249 (M+, 31), 203 (100).
HRMS (EI): m/z [M]+ calcd for C11H11N3O4: 249.0749; found:
249.0756.
Synthesis 2011, No. 4, 571–576 © Thieme Stuttgart · New York